Submitted by Erika Demachki (erikademachki@gmail.com) on 2014-09-29T21:15:45Z
No. of bitstreams: 2
Dissertação Mestrado Rossana 28-11-12 3pdf.pdf: 712072 bytes, checksum: e167dad92cf8edd8b25298ca4f1f6951 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2014-09-29T21:42:41Z (GMT) No. of bitstreams: 2
Dissertação Mestrado Rossana 28-11-12 3pdf.pdf: 712072 bytes, checksum: e167dad92cf8edd8b25298ca4f1f6951 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-09-29T21:42:41Z (GMT). No. of bitstreams: 2
Dissertação Mestrado Rossana 28-11-12 3pdf.pdf: 712072 bytes, checksum: e167dad92cf8edd8b25298ca4f1f6951 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Previous issue date: 2008-08-29 / INTRODUCTION: The cervical cancer is the third most frequent malignant neoplasia among women in Brazil and it is responsible for the fourth cause of death for cancer. It is related among other causes to persistent infection by human papillomavirus. Doubts persist if HPV type could influence the tumor prognosis. OBJECTIVE: To study the prevalence of HPV 18 and HPV 16 in women presenting cervical cancer in clinic stage Ib, treated by radical hysterectomy with linfadenectomy, establishing prognostic correlation. METHODS: A retrospective cohort study, including 86 pacients with cervical cancer Ec I, submitted to radical hysterectomy, in a single center, in which were analysed the known prognostic factors and the positivity to HPV by PCR. Univariate analysis was performed, with Kaplan-Meir curves, for survival estimative. RESULTS: The prevalence of HPV 16 infection was 65.3% and HPV 18 prevalence was 33.3%. To both virus the prevalence was 26.9%. The overall survival for women presenting HPV 18 infection, in sixty months, was 91% and those women without HPV 18 infection, the overall survival was 96%. The overall survival for women with and without HPV16 infection was 94% and 96%, respectively. The disease free survival was not influenced by the presence of either virus. CONCLUSION: In the present study, in spite of the high prevalence of HPV 18 and HPV 16, the presence of these tipes of HPV have not influenced the prognosis of EcI cervixl cancer in women submitted to radical histerectomy. / INTRODUÇÃO: O câncer do colo uterino é a terceira neoplasia maligna mais frequente entre as mulheres no Brasil e entre elas é responsável pela quarta causa de morte por câncer. Está relacionado, entre outras causas, à infecção persistente pelo papilomavirus humano. Persistem dúvidas se o tipo de HPV exerce influência sobre o prognóstico da doença. OBJETIVO: Estudar a prevalência do HPV 18 e HPV 16 em mulheres com o câncer do colo uterino no estádio clínico Ib, tratadas por histerectomia radical com linfadenectomia pélvica, procurando estabelecer correlação prognóstica. MÉTODOS: Estudo de coorte retrospectivo, incluindo 86 pacientes com câncer do colo uterino Ec I, submetidas à histerectomia radical, em um único centro, no qual foram analisados os fatores prognósticos já conhecidos, além da presença do HPV 16 e 18, pesquisado por PCR. Utilizou-se análise univariada, com curvas de Kaplan-Meir, para estimativa de sobrevida. RESULTADOS: A prevalência do HPV 16 no grupo estudado foi de 65,3% e a prevalência do HPV 18 foi de 33,3%. A prevalência dos casos em que houve infecção por ambos os vírus foi de 26,9%. A sobrevida global para as mulheres portadoras do HPV 18, aos sessenta meses, foi de 91% e nas que não eram portadoras desse vírus foi de 96% (NS). Já para as mulheres portadoras do HPV 16 a sobrevida global foi de 94% e para as não portadoras desse vírus a sobrevida foi 96% (NS). A sobrevida livre de doença também não foi influenciada pela presença do HPV 18 e do HPV 16. CONCLUSÃO: No presente estudo, apesar da alta prevalência do HPV 18 e do HPV 16, a presença desses tipos de HPV não influenciaram o prognóstico das pacientes portadoras de câncer de colo uterino, Ec I, submetidas à histerectomia radical.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.bc.ufg.br:tede/3217 |
| Date | 29 August 2008 |
| Creators | Zampronha, Rossana de Araújo Catão |
| Contributors | Freitas Jr, Ruffo, Murta, Eddie Fernando Cândido |
| Publisher | Universidade Federal de Goiás, Programa de Pós-graduação em Medicina Tropical e Saúde Publica (IPTSP), UFG, Brasil, Instituto de Patologia Tropical e Saúde Pública - IPTSP (RG) |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | Portuguese |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UFG, instname:Universidade Federal de Goiás, instacron:UFG |
| Rights | http://creativecommons.org/licenses/by-nc-nd/4.0/, info:eu-repo/semantics/openAccess |
| Relation | 6085308344741430434, 600, 600, 600, -7769011444564556288, 1767748423488408711, Bachtiary B, Obermair A, Dreier B, Birner P, Breitenecker G, Knocke T-H, Selzer E, Potter R 2002. Impact of multiple HPV infection on response to treatment and survival in pacients receiving radical radiotherapy for cervical cancer. Int J Cancer. 102:237-243. Bellone S, Percorelli S, Cannom MJ, Santin AD 2007. Advances in dendritic-cell- based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther. 7: 1473-86. Beral V, Hannaford P, Kay C. 1988. Oral contraceptive use and malignancies of the genital tract. Lancet. 1331. Bosch FX, Maños MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah K V. 1995. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. J Natl Cancer Inst. 87: 796-802. Buckley JD, Harris RW, Doll R, Vessey MP, Willioms PT 1981. Case-control study of the husbands of women with dysplasia or carcinoma of cervix uteri. Lancet. 2:1010. 71 Burger RA, Monk B J, Kurosaki T, Anton-Culver H ,Vasilev SA, Berman ML, Wilczinski SP 1996. Human papillomavirus type 18: Association with poor prognostic in early stage cervical cancer. Natl Cancer inst. 88: 1361-8. Cameron JE, Hagensee ME 2007. Human papillomavirus infection and disease in HIV⁺ individual. Cancer Treat Res. 133: 185-213. Carvalho CRN, Ribalta LCL. Papilomavírus Humano: Considerações Gerais, Epidemiologia e Importância dos Co-fatores na Carcinogênese. In: Martins NV, Ribalta JCL, Editores. Patologia do Trato Genital Inferior. São Paulo: Roca, 2005, 216 a 226. Carr J, Gyorfi T 2000. Human papillomavirus epidemiology, transmission and pathogenesis Clin.Lab Me. 20: 235-255. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah HV, Sanjosé S, Eluf-Neto J, Ngelangel AC, Chichareon S, Smirh FS, Herrero R, Francheschi S 2002. Male circumcision, penile human papillomavirus infection and cervical cancer in female partners. N Eng J Med April 11: 346 (15): 1105-1112. Castellsagué X, Bosch FX, Munhoz N 2002. Enviromental co-factors in HPV carcinogenesis. Virus Research.89: 191-199. 72 Castro FA, Haimila K, Pasanen K, Kaasila M, Patama T, Partanen J, Surcel HM, Pukkala E, Lehtinem M 2007. Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland. Int J STD AIDS. 18:672-9. Cavalcante SMB, Zardo LG, Passos MRL, Oliveira LHS 2000. Epidemiological aspects of human papillomavirus infection and cervical cancer in Brazil. J Infect. 40: 80-87 Chi DS, Abu-Rustum NR, Hoskins WJ. Cancer of the cervix. In: Rock JA, Jones HW, Editors. TE LINDE’S OPERATIVE GYNECOLOGY. Philadelphia: Linppincot Williams & Wilkins, 2003, 1373 a 1444. Cincestav. HTTP//:www.cinvestav.mx ; Acessado em 27/08/2008. Corrêa C M 2007. Prevalência e multiplicidade do Papilomavirus Humano (HPV) na cérvice uterina de mulheres infectadas pelo vírus da Imunodeficiência Humana (HIV), em estudo multicêntrico. Dissertação de mestrado. Ciências da Reprodução, Patologia mamária e Ginecológica e Perinatologia. Faculdade de Medicina da Universidade Federal de Minas. Curado MP, Martins E, Freitas-Junior R, Silva EMB: Incidence of cervix cancer in Goiânia. A descriptive analyse 1988 – 2002. Final Program and Abstracts. 27ª 73 Annual Meeting of the International Association of Cancer Registtries.IACR 2005 Theme: Cancer in low-resource populations.Entebbe, Uganda.13-15. Datta NR, Kumar P, Singh S, Gupta D, Srivastava A, Dhole TN 2006. Does retreatment Human Papillomavirus (HPV) titer predict radiation response and survival outcomes in cancer cervix? A pillot study. Gynecol Oncol. 103:100-5. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F 1990. Prospective surgical-pathological study of disease-free interval on patients with stage IB Squamous cell carcinoma of the cervix: a Gynecology Oncology Group study. Gynecol Oncol. 38: 352-7. De Villiers EM, Fauquet C, Braker TR, Bernard H-U, zur Hausen H 2004. Classification of papillomaviruses. Virology. 324: 17-27. Delgado-Enciso I, Cervantes-Garcia D, Martinez-Dávila IA, Ortiz-López R, Alemany-Bonastre R, Silva-Platas CI, Lugo-Trampe A, Barrera-Saldaña HA, Galván-Salazar HR, Coronel-Tene CG, Sánchez-Samtillán CF, Rojas-Martinez A 2007. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms. J Gene Med 9: 852-61. 74 D’Souza Gypsyamber, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML, 2007. Case-control Study of Human Papillomavirus and Oropharyngeal Cancer. N Engl J Med; 356: 1944-56. Frazer I F, Cox JT, Mayeaux Jr EJ, Franco LE, Moscicki A-B, Palefsky JM, Ferris DG, Ferenczy AS, Villa LL 2006. Advances in prevention of cervical cancer and other human papilloma virus-related diseases.Pediatr Infect Dis J. 25: 565-581. Fregnani JH, Latorre MR, Novik PR, Lopes A, Soares FA 2006. Assessment of pelvic limph node micrometastatic disease in stages Ib and IIa of carcinoma of the uterine cervix. Int J Gynecol Cancer. 16: 1188-94. Frisch M, Biggar RJ, Goedert JJ 2000. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Nat Cancer Inst. 92: 1500-2000. Fuller AF, Elliott N, Kosloff C, Hoskins WJ, Lewis JL 1989. Determinants of increased risk for recurrence in pacients undergoing radical histerectomy for stage IB and II A carcinoma of the cervix. Gynecol Oncol. 33: 34 -9. Gallup DG, Harper RH, Stock RJ 1985. Poor prognosis in pacients with adenosquamous cell carcinoma of the cervix. Obst Gynecl. 65:416-22. 75 Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Menso S, De Nictolis M 1998. The hole of human papillomavirus DNAs in cervical carcinoma with 72 Kilodalton metaloproteinase immunostaining. Cancer. 82: 886-91. Girardi F, Fuchs P, Haas J 1992. Prognostic importance of human papillomavirus type 16 DNA in cervical cancer. Cancer. 69: 2502-4. Gonçalves MA, Donadi EA 2004. Immune cellular response to HPV: current concepts. Braz J Infect Dis. 8:1-9. Gram IT, Macaluso M, Stalsberg H 1992. Oral contraceptive and the incidence of cervical intraepithelial neoplasia. Am J Obstet Gynecol. 167:40. Graflund M, Sorbe B, Sigurdardóttir S, Karlsson M 2004. HPV-DNA, vascular space invasion, and their impact on the clinical outcome in early-stage cervical carcinomas. Int J Gynecol Cancer. 14: 896-902. Gregoire L, Cubilla AL, Reuter VE, Haas GP, Lancaster WD 1997. Preferencial association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst. 87:1705-1709. Hart K, Han I, Deppe G, Malviya V, Malone JJr, Christensen C 1997. Postoperative radiation for cervical cancer with pathologic risk factors. Int J Radiat Oncol Biol Phis. 37:833-8. 76 Ho GYF, Biernan R, Beardley L, Chang CJ, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachesy R, Lewis R, Romney S 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 338: 423-428. Huang HJ, Huang SL, Lin CY, Lin RW, Chao FY, Chen MY, Chang TC, Hsueh S, Hsu KH, Lai CH 2004. Human papillomavirus genotyping by a polymerase chain reaction-based method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int Gynecol Cancer. 14: 639-49. Yazigi R, Saldstad J, Munhoz AK, Choi DJ, Nguyen PD, Risser R 1990. Adenosquamous carcinoma of the cervix: prognosis in stage Ib. Obstetric Gynecol. 75 :1012-5. Jansen K, Shaw AR 2004.Human papillomavirus vaccines and prevention of cervical cancer. Ann Rev Med. 55: 319-331. Jones MW, Kounelis S, Papadaki H, Bakker A, Swalsky PA, Woods J, Finkelstein SD 2000. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/tumor suppressor gene alterations and papillomavirus genotyping. Int J Gynecol Pathol. 19: 110-117. 77 Kaplan, ELMP 1958.Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53: 457. Kjaer SK, van den Brule, Paull G, Svare E I, Sherman ME, Thonsem B L, Suntum M, Bock JE, Poll P A, Meijer CJLM 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraephitelial lesions in young women: population based prospective follow-up study. BMJ 325. Kuper H, Boffetta P, Adami H O 2002. Tobacco use and cancer causation: association by tumor type.J Int Med. 252: 206-224. Lai CH, Chang CJ, Huang HJ , Hsueeh S, Chao A, Yang J-E, Lin G-T, Huang S-L, Hong J-H, Chou H-H, Wu T-I, Huang K-G, Wang C-C,Chang T-C 2007.Role of human papillomavirus genotype in prognosis of early stage cervical cancer undergoing primary surgery. J Clin Oncol. 25: 3628-34. Logan WPS 1953. Marriage and childbearing in relation to cancer of the breast and uterus. Lancet II: 1199. Maciag PC, Schletcht NF, Souza PSA, Franco EL, Villa2ª LL, Petzel-Erler ML 2000. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women.Cancer epidemiol Bio Prev. 9: 1183-1191. 78 Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter P, Galloway DA 2001. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarker Prev. 10: 171-177. Meisels A & Fortin R 1976. Condylomatous Lesions of Cervix and Vagina Cytologic Patterns. Acta Cytol. 20: 505-509. Meigs JV 1945. The Wertheim operation for carcinoma of the cervix. Am J Obstet Gynecol 49: 542. Ministério da saúde do Brasil. Instituto Nacional do Câncer. Câncer do colo do útero. Disponível em http://www.inca.gov.br/conteudo_view.asp?ID=326. Monsonego J 2007. Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues. Presse Med 36: 640-66. Montesano R, Hall J 2001. Enviromental causes of human cancers. Eur J Cancer. 37: S67-S82. Moreira MAR, Longato-Filho A, Toromarus E, Queiroz G, Jubé LF, Pinto SA, Schimitt FC 2006. Investigation of human papillomavirus by hybrid capture II in 79 cervical carcinomas including 113 adenocarcinomas and related lesions. Int J Gynecol Cancer. 16: 586-590. Moreno V, Bosch FX, Munoz N, Meijer CJLM, Shah HV, Waalboomers JAMM, Herrero R, Francheschi S 2002. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. The Lancet. 359: 1085. Moriaty AT, Wilbur D.Those gland problems in cervical cytology: Faith or fact? Observations from the Bethesda 2001 Terminology Conference 2003. Diagn Cytopathol. 28: 171-4. Moscicki A, Shiboskis S , Broering J, Jay Naomi, Powel K, Clayton L, Darragh TM, Brescia R, Kanowitz S, Miller S, Stone J, Hanson E, Palefsky J 1998. Natural history of papillomavirus infection as measured by repeated DNA testing in adolescent and young woman. J Pediatr. 132: 277-284. Munhoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugarza I, Gili M, Liladiu P, Navarro C Martos C, Ascunce N 1992. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer. 52: 743-749. 80 Munhoz N, Bosch FX, Sanjose S, Herrero R, Castellsague X, Shah KV 2003. Epidemiologic classification of human papillomavirus types associated with cancer. N Engl J Med. 348: 518-27. Nagai Y, Toma T, Moromizato H, Maehama T, Asato T, Kariya K, Kanazawa k 2004.Persistence of Human papilomavírus Infection as a Predictor for recurrence in carcinoma of the cervix after radiotherapy. Am J Obstet Gynecol. 191: 1907-13. Nakagawa S, Yoshikawa H, Onda T, Kawana T, Iwamoto A, Taketani Y 1996. Type of Human Papillomavirus is related to clinical features of cervical carcinoma. Cancer. 78: 1935-41. Nobeyama H, Sumi T, Misugi F, Okamoto E, Hattori K, Matsumoto Y, Yasui T, Honda K-I, Ishiro O 2004. Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. Int J Med. 101-105. Parkin DM, Muir CS, Whelan SL, Ferlay J, Teppo L, Thomas DB 2002. Cancer incidence in five continents. Lyon (France) IARC. Sci Publi nº155. Padilla-Paz LA 2005. Human papillomavirus vaccine: History, immunology, current status, and future prospects. C Obstet Gynecol. 48: 226-40. 81 Palefsky JM 2003. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highy active antiretroviral therapy. Current Opinion Oncology. 15: 382-388. Peters WA 3rd, Liu PY, Barret RJ 2nd , Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr 2000. Concurent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy with pelvic alone as adjuvant therapy after radical surgery high risk early stage cancer of the cervix. J Clin Oncol.18: 1606-13. Pilch H, Ganzel S, Schäuffer U, Tanner B, Brockerhoff P, Maeurer M, Höckel M, Hommel G, Knapstein PG 2001. The presence of HPV DNA in cervical cancer: correlation with clinical-pathologic parameters and significance: 10 years experience at the department of obstetrics and gynecology of the Mainz University. Int J Gynecol Cancer. 11: 39-48. Pintos J, Blackm MJ, Sadeghi N, Gladiriav P, Zeitouni AG, Viscidi RP, Herrero R, Coutlée F, Franco EL 2008. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncology. 44: 242-50. Poletti PA, Halfon A, Marti MC 1998. Papillomavirus and anal carcinoma. Int J Colorectal Dis. 13: 108-111. 82 Rabelo-Santos SH, Zeferino L, Villa LL, Sobrinho JL, Amaral RG, Magalhães AV 2003. Human papillomavirus prevalence among Goiânia, Brazil. Mem Inst Oswaldo Cruz. 98: 181-184. Rambout L, Hopkins L, Hutton B, Fergusson D 2007. Prophylatic vaccine against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 177 : 469 – 479. Reeves WC, Brinton LA, Brennes MM, Quiroz E, Rauls WE, De Britton RC 1985. Case-control study of cervical cancer in Herrera Province, Republic of Panama. Int J Cancer. 36: 55. Rigoni-Sterne, D 1842. Fatti statistici relativi alle mallatie cancrose che seroirone di base alle poche cose dette dal dot. G Sevire Progr Patol Terap 2: 507. Rojel J 1953.The interrelation between cervical cancer and syphilis. Acta Pathol Microbiol Scand. 97: 1. Rose Ragin, CC & Taioli E 2008. Second Primary head and neck tumor risk in pacients with-SEER data analysis. Head Neck. 30: 58-66. Rolón PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meur CJLM, Walboomers JMM 2000. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer. 85: 486-491. 83 Sarkar FH, Crissman JD 1990. Detection of human papilloma virus DNA sequences. Biothecniques. 2: 180-5. Sarkar FH, Miles BJ, Plieth DH, Crissman JD 1992. Detection of human papillomavirusin squamous neoplasm of the penis. J Urol. 147: 389-92. Schiffman M, Kajaer SK. Chapter 2: Natural History of anogenital human Papillomavirus Infection and Neoplasia. J Natl Cancer Inst Monogr. 2003; 31:14. Schwartz SM, Daling JR, Shera KA, Madeleine MM, Mcknight B, Galloway DA, Porter Pl, McDougal JR 2001. Human papillomavirus and prognosis of invasive cervical cancer: A population-based study. J Clin Oncol. 19: 1906-1915. Singh RK, Maulik S, Mitra S, Mondel R, Basu SP, Raychwdhury S, Panda CK 2006. Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients correlation with recurrence of the disease. Int Gynecol Cancer. 16: 1048-1054. SPAIS/SES-GO- Superintendência de Políticas de Atenção Integral à Saúde/ Secretaria de Estado de Goiás 2006; Boletim epidemiológico, ano 7 nº 24 jan/fev e março. 84 Strander B, Ryd W, Wallin K-L, Wärleby B, Zheng B, Milson I, Gharizadeh B, Pourmand N, Anderson-Ellström A 2007. Does HPV-Atatus 6-12 months after treatment of high grade dysplasia in uterine cervix predict long term recurrence? EJC. 43: 1849-1855. Towne JE 1955. Carcinoma of the cervix in nulliparous and celibate woman. Am J Obstet Gynecol. 69: 606. Ursin G, Peters RK, Henderson BE, d’Ablaing G3rd, Monroe KR, Pike MC 1994. Oral contraceptive use and adenocarcinoma of cervix. Lancet. 344: 1390-4. van Muyden RCPA, Harmsel BWA, Smedts FMM , Hermans J, Kuijpers J C, Raikhlin N T, Petrov S, Lebedev A, Ramaekers FCS, Trimbos JB, Kleter B, Quint QGV 1999. Detection and typing of human pappillomavirus in cervical carcinomas in Russian women. Cancer. 85: 2011-6. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Scerman ME, Wangs S, Clayman B, Burk RD 2004. Seroreactivity to human papillomavirus (HPV) types 16, 18 or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 13: 324-327. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG 1999. Recurrent cervical carcinoma after primary radical surgery. Am J Obstet. 181: 518-24. 85 Waggoner SE 2001. Cervical cancer. Lancet. 361: 2217-2225. Waggoner SE, Fuhrman B, Darcy K, Parham G, Lucci JA, Monk BJ 2003. Influence of smoking on progression-free and overall survival in women with stage II-B, III-B and IVA cervical carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Soc Gynecol Oncol 71. Walbbomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snuders PJ, Peto J, Meijer CJM, Muñoz N 1999. Human Papillomavirus is a necessary cause of invasive cervical cancer wordwide. J Pathol 189: 12-19. Waterhause J, Muir C, Shammugaratnam K 1982. Cancer Incidence in five continents. Lyon: International Agency for Research on Cancer. Winkelstein W 1977. Smoking and cancer of uterine cervix: hypothesis Am J Epidemiol 106: 257. Winkestein W, Shillitoe E J, Brand R 1984. Further comments on cancer of uterine cervix, smoking and herpesvirus infection. Am J Epidemiol. 119: 1 Wright NH, Vessey MP, Kenward B 1978. Neoplasia and dysplasia of the cervix uteri and contraception. Br J Cancer. 38: 273. 86 Wright JD, Li J, Gerard DS, Zhang Z, Huettner PC, Powell MA, Gibb RK, Herzog TJ, Mutch DG, Trinkaus KM, Rader JS 2005. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol. 98: 84-91. Yamazawa K, Matsui H, Seki K et al 2000. Human papillomavirus-positive well differentiated adenocarcinoma of the uterine cervix: a case report and review of the literature. Gynecol Oncol. 77: 473-477. Young RH, Scully RE 1989. Villoglandular papillary adenocarcinoma of the uterine cervix.A clinicopathological analysis of 13 cases. Cancer 63: 1773-1779. Zielimski CD, Rozendaal I, Voohorst FJ 2003. HPV testing can reduce the number of follow up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 91: 67-73. Zhou J, Sun XY, Stenzel D, Farzer IH 1991. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV vireo-like particles.Virology. 185: 251-257. Zunzuneghi MV, King MC, Coria CF, Charlet J 1986. Male influence on cervical cancer risk. Am J epidemiol. 123: 302. |
Page generated in 0.0099 seconds